Prime Medicine Inc (PRME) Directors and Executive Officers

Officers & Directors

Keith Gottesdiener
President and Chief Executive Officer (Principal Executive Officer)

Allan Reine
Chief Financial Officer (Principal Financial Officer)

Carman Alenson
Chief Accounting Officer (Principal Accounting Officer)

Thomas Cahill
Director

David Schenkein
Director

Kaye Foster
Director

Michael Kelly
Director

Wendy Chung
Director

Jeff Marrazzo
Director

Robert Nelsen
Director ,

Prime Medicine Inc currently has 146 employees.

News about Prime Medicine Inc Key Personnel

Prime Medicine Charts a New Course in Genetic Medicine: Innovative Strategies and Strong Financial Performance Pave the Path Ahead,

Prime Medicine s Strategic Advancements in Genetic MedicinePrime Medicine Inc. is making waves in the biotechnology sector with its innovative approach to genetic medicine, capitalizing on its prime editing platform to establish a strategically focused pipeline. With an emphasis on high-value programs in core therapeutic areas, the company aims to set a strong foothold in the rapidly evolving landscape of genetic therapeutics. Key Developments in Prime MedicineIn a recent announcement, Prime Medicine unveiled its plan to prioritize a set of programs that are expected to deliver high returns on investment. The modularity of the Prime Editing Platform is a significant advantage, allowing the company to genera...

Prime Medicine Announces Upsized Public Offering as it Pursues Groundbreaking Genetic Therapies

In a groundbreaking move, Prime Medicine, Inc. (Nasdaq: PRME), a leading biotechnology company dedicated to revolutionizing the field of genetic therapies, has announced the pricing of an underwritten upsized public offering. This strategic move underscores Prime Medicine s commitment to delivering a new class of differentiated one-time curative genetic therapies.
The public offering includes 19,200,001 shares of Prime Medicine s common stock, priced at $6.25 per share. Additionally, the company will offer pre-funded warrants to certain investors, allowing them to purchase 3,200,005 shares of common stock at a public offering price of $6.24999 per pre-funded warrant. It is important to note tha...